AVROBIO Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing transformative, life-changing therapies that have the potential to transform patients’ lives in a single dose.
The catalyst for creating AVROBIO is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease.
AVROBIO was founded by industry leaders with unmatched scientific, business and manufacturing expertise in the field of cell and gene therapy.
Our scientific founders have developed unique and innovative technologies which, after many years of intensive research, have reached human clinical stage of development.
A unifying theme across our cell therapies is the expert design and production of the most efficient gene delivery system in the world.